Sprout Health Last on our list, we have Sprout Health with a score of 7 out of 10
Retatrutide, a triple agonist targeting gastric inhibitory polypeptide (GIP), GLP-1, and glucagon receptors, has achieved highly promising outcomes in its phase 2 trial [22], with weight loss up to 24%
Addressing Cardiovascular Risk Factors Semaglutide has been shown to reduce the risk of major adverse cardiovascular events (MACE) such as heart attack, stroke, or cardiovascular death in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors
Retatrutides Impact In clinical trials, retatrutide produced larger LDL reductions than semaglutide or tirzepatide, even when adjusting for weight loss
In addition, approximately 1 in 3 participants (31.6%) who received cagrilintide achieved a weight loss 15%, compared to approximately 1 in 20 participants (4.7%) who received placebo